Does Methylphenidate Normalize Brain Dysfunction During Fear Learning in Adolescents With Disruptive Behavior Disorders?

Research output: Contribution to journalEditorial

Abstract

Conduct disorder (CD) and oppositional defiant disorder (ODD), collectively termed disruptive behavior disorders (DBDs), are a major cause of impairment and suffering in those affected by these conditions and their families and communities. The prevalence of DBDs is estimated at 5-14% in school-aged children,1 and they are costly to society and linked with negative adult outcomes.2 Unfortunately, few effective psychological treatments are available, and there is a lack of evidence-based pharmacological treatments for DBDs.3 The present study by Van Lith et al.4 investigates whether acute methylphenidate administration normalizes low brain activity during fear conditioning in adolescents with DBDs within the context of a randomized controlled trial. While the group of DBD youth who were given placebo showed reduced amygdala activity during fear conditioning relative to healthy controls, those taking methylphenidate showed an apparent normalization of amygdala activity.

Original languageEnglish
Pages (from-to)911-913
Number of pages3
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume57
Issue number12
DOIs
Publication statusPublished - 1 Dec 2018

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Cite this

@article{d54ff3e29c2d4ecbae198c56e1e9cf9b,
title = "Does Methylphenidate Normalize Brain Dysfunction During Fear Learning in Adolescents With Disruptive Behavior Disorders?",
abstract = "Conduct disorder (CD) and oppositional defiant disorder (ODD), collectively termed disruptive behavior disorders (DBDs), are a major cause of impairment and suffering in those affected by these conditions and their families and communities. The prevalence of DBDs is estimated at 5-14{\%} in school-aged children,1 and they are costly to society and linked with negative adult outcomes.2 Unfortunately, few effective psychological treatments are available, and there is a lack of evidence-based pharmacological treatments for DBDs.3 The present study by Van Lith et al.4 investigates whether acute methylphenidate administration normalizes low brain activity during fear conditioning in adolescents with DBDs within the context of a randomized controlled trial. While the group of DBD youth who were given placebo showed reduced amygdala activity during fear conditioning relative to healthy controls, those taking methylphenidate showed an apparent normalization of amygdala activity.",
author = "Graeme Fairchild",
year = "2018",
month = "12",
day = "1",
doi = "10.1016/j.jaac.2018.07.879",
language = "English",
volume = "57",
pages = "911--913",
journal = "Journal of the American Academy of Child and Adolescent Psychiatry",
issn = "0890-8567",
publisher = "Elsevier",
number = "12",

}

TY - JOUR

T1 - Does Methylphenidate Normalize Brain Dysfunction During Fear Learning in Adolescents With Disruptive Behavior Disorders?

AU - Fairchild, Graeme

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Conduct disorder (CD) and oppositional defiant disorder (ODD), collectively termed disruptive behavior disorders (DBDs), are a major cause of impairment and suffering in those affected by these conditions and their families and communities. The prevalence of DBDs is estimated at 5-14% in school-aged children,1 and they are costly to society and linked with negative adult outcomes.2 Unfortunately, few effective psychological treatments are available, and there is a lack of evidence-based pharmacological treatments for DBDs.3 The present study by Van Lith et al.4 investigates whether acute methylphenidate administration normalizes low brain activity during fear conditioning in adolescents with DBDs within the context of a randomized controlled trial. While the group of DBD youth who were given placebo showed reduced amygdala activity during fear conditioning relative to healthy controls, those taking methylphenidate showed an apparent normalization of amygdala activity.

AB - Conduct disorder (CD) and oppositional defiant disorder (ODD), collectively termed disruptive behavior disorders (DBDs), are a major cause of impairment and suffering in those affected by these conditions and their families and communities. The prevalence of DBDs is estimated at 5-14% in school-aged children,1 and they are costly to society and linked with negative adult outcomes.2 Unfortunately, few effective psychological treatments are available, and there is a lack of evidence-based pharmacological treatments for DBDs.3 The present study by Van Lith et al.4 investigates whether acute methylphenidate administration normalizes low brain activity during fear conditioning in adolescents with DBDs within the context of a randomized controlled trial. While the group of DBD youth who were given placebo showed reduced amygdala activity during fear conditioning relative to healthy controls, those taking methylphenidate showed an apparent normalization of amygdala activity.

UR - http://www.scopus.com/inward/record.url?scp=85057845544&partnerID=8YFLogxK

U2 - 10.1016/j.jaac.2018.07.879

DO - 10.1016/j.jaac.2018.07.879

M3 - Editorial

VL - 57

SP - 911

EP - 913

JO - Journal of the American Academy of Child and Adolescent Psychiatry

JF - Journal of the American Academy of Child and Adolescent Psychiatry

SN - 0890-8567

IS - 12

ER -